Safety of SARS-CoV-2 Vaccination in Patients with Vascular Malformations: Patient-Reported Adverse Vaccine Reactions.

Publication date: Jun 25, 2023

Objectives: Concerns among susceptible individuals, especially those with vascular malformations, have been raised by reports of thromboembolism following the administration of the SARS-CoV-2 vaccination against coronavirus disease 2019 (COVID-19). This study’s goal was to assess any negative side effects that patients with vascular malformations who received the SARS-CoV-2 vaccine reported after receiving it. Materials and Methods: Through the three patient groups for vascular malformations in Japan in November 2021, a questionnaire was distributed to patients with vascular malformations who were 12 years of age or older. Multiple regression analysis was used to find relevant variables. Results: A total of 128 patients responded, representing a response rate of 58. 8%. Ninety-six participants (75. 0%) had received at least one dose of SARS-CoV-2 vaccine. In total, 84 (87. 5%) and 84 (89. 4%) subjects experienced at least 1 general adverse response following dose 1 and dose 2, respectively. Adverse reactions related to vascular malformations were reported by 15 participants (16. 0%) after the 1st dose and 17 (17. 7%) after the 2nd dose. Notably, no case of thromboembolism following vaccination was reported. Conclusion: The rate of vaccine-related adverse reactions in patients with vascular malformations is not different from that reported in the general population. There is no report of life-threatening responses in the research population.

Concepts Keywords
Coronavirus adverse reactions
Japan COVID-19
November vaccination
Patient vascular anomalies
vascular malformations


Type Source Name
disease VO vaccination
disease MESH Vascular Malformations
disease VO vaccine
disease MESH thromboembolism
disease MESH coronavirus disease 2019
disease VO dose
disease VO population
disease VO report
disease MESH anomalies

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *